Enlivex Therapeutics Ltd (ENLV)

$1.07 +0.02 (1.42%)
Market Cap 25.63M
Revenue (ttm) 0.00
Net Income (ttm) -15.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 119,500
Avg Vol 550,712
Day's Range N/A - N/A
Shares Out 24.29M
Stochastic %K 27%
Beta 0.90
Analysts Strong Sell
Price Target $10.00

Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 620 8072
Address:
14 Einstein Street, Ness Ziona, Israel
THEJSAENZ
THEJSAENZ Oct. 21 at 8:01 PM
$ENLV 93k order at 1.09
1 · Reply
THEJSAENZ
THEJSAENZ Oct. 21 at 7:13 PM
$ENLV 26k order at 1.08. Someone knows something maybe!?
1 · Reply
DianeElmore377
DianeElmore377 Oct. 20 at 4:31 PM
$ENLV driving breakthroughs in medicine; AITX driving breakthroughs in automation — profitability achieved, growth now accelerating.
0 · Reply
kellymone2
kellymone2 Oct. 16 at 11:44 AM
$ENLV What's your average? Mine is 1,61$
2 · Reply
Mrsdelbusto1
Mrsdelbusto1 Oct. 15 at 12:27 PM
$ENLV when it runs it will run!
2 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 9:17 PM
Keep a close watch on CMCT! $LITE $NEXT $ENLV $BLNK 3
0 · Reply
Nicks_pics
Nicks_pics Oct. 7 at 5:44 PM
$ENLV Link to the D. Boral Capital webinar recording. Recommend listening if you’re invested or considering a position. https://youtu.be/WP3iAXss90g
0 · Reply
Roraon
Roraon Oct. 6 at 8:37 PM
$ENLV Fantastic day for ENLV!!!.
0 · Reply
Stellabella50
Stellabella50 Oct. 6 at 8:22 PM
$ENLV making a little move here.
0 · Reply
THEJSAENZ
THEJSAENZ Oct. 6 at 7:57 PM
$ENLV nice change of pace for this one
0 · Reply
Latest News on ENLV
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Sep 29, 2025, 8:15 AM EDT - 26 days ago

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

Sep 11, 2025, 8:00 AM EDT - 6 weeks ago

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Sep 9, 2025, 8:00 AM EDT - 6 weeks ago

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

Aug 18, 2025, 7:45 AM EDT - 2 months ago

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

Aug 14, 2025, 8:30 AM EDT - 2 months ago

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Jul 28, 2025, 8:30 AM EDT - 3 months ago

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Jun 10, 2025, 8:30 AM EDT - 4 months ago

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Enlivex Selected to Present at Israeli BioMed 2025 Conference

May 20, 2025, 8:00 AM EDT - 5 months ago

Enlivex Selected to Present at Israeli BioMed 2025 Conference

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Apr 23, 2025, 8:30 AM EDT - 6 months ago

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Apr 21, 2025, 8:30 AM EDT - 6 months ago

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Apr 3, 2025, 8:00 AM EDT - 7 months ago

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Mar 17, 2025, 8:00 AM EDT - 7 months ago

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Mar 4, 2025, 4:30 PM EST - 8 months ago

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Mar 3, 2025, 8:22 AM EST - 8 months ago

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Feb 18, 2025, 6:20 AM EST - 8 months ago

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jan 10, 2025, 9:00 AM EST - 10 months ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Dec 11, 2024, 8:30 AM EST - 11 months ago

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Dec 5, 2024, 10:49 AM EST - 11 months ago

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Nov 26, 2024, 10:15 AM EST - 11 months ago

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Nov 14, 2024, 8:00 AM EST - 1 year ago

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 30, 2024, 9:00 AM EDT - 1 year ago

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GP

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 19, 2024, 9:00 AM EDT - 1 year ago

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

May 29, 2024, 4:15 PM EDT - 1 year ago

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

May 28, 2024, 8:12 AM EDT - 1 year ago

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Apr 16, 2024, 7:50 AM EDT - 1 year ago

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Apr 11, 2024, 2:58 PM EDT - 1 year ago

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Apr 11, 2024, 8:05 AM EDT - 1 year ago

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mar 22, 2024, 10:50 AM EDT - 1 year ago

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

UMAC

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Feb 26, 2024, 8:30 AM EST - 1 year ago

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Feb 21, 2024, 8:30 AM EST - 1 year ago

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Jan 17, 2024, 8:00 AM EST - 1 year ago

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Dec 20, 2023, 8:00 AM EST - 2 years ago

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Jul 31, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Enlivex to Present at the 2023 Jefferies Healthcare Conference

Jun 6, 2023, 8:00 AM EDT - 2 years ago

Enlivex to Present at the 2023 Jefferies Healthcare Conference

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

May 31, 2023, 8:04 AM EDT - 2 years ago

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

May 8, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Apr 19, 2023, 8:00 AM EDT - 2 years ago

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Enlivex Appoints Andrew Singer to its Board of Directors

Apr 17, 2023, 8:00 AM EDT - 2 years ago

Enlivex Appoints Andrew Singer to its Board of Directors

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

Apr 14, 2023, 9:40 AM EDT - 2 years ago

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors

Apr 12, 2023, 10:45 AM EDT - 2 years ago

Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors

Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates

Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors

Apr 3, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors

Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers

Mar 20, 2023, 8:00 AM EDT - 2 years ago

Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Feb 15, 2023, 8:00 AM EST - 2 years ago

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Jan 25, 2023, 8:37 AM EST - 2 years ago

Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update

Dec 5, 2022, 8:00 AM EST - 3 years ago

Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update

Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Nov 15, 2022, 8:00 AM EST - 3 years ago

Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

THEJSAENZ
THEJSAENZ Oct. 21 at 8:01 PM
$ENLV 93k order at 1.09
1 · Reply
THEJSAENZ
THEJSAENZ Oct. 21 at 7:13 PM
$ENLV 26k order at 1.08. Someone knows something maybe!?
1 · Reply
DianeElmore377
DianeElmore377 Oct. 20 at 4:31 PM
$ENLV driving breakthroughs in medicine; AITX driving breakthroughs in automation — profitability achieved, growth now accelerating.
0 · Reply
kellymone2
kellymone2 Oct. 16 at 11:44 AM
$ENLV What's your average? Mine is 1,61$
2 · Reply
Mrsdelbusto1
Mrsdelbusto1 Oct. 15 at 12:27 PM
$ENLV when it runs it will run!
2 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 9:17 PM
Keep a close watch on CMCT! $LITE $NEXT $ENLV $BLNK 3
0 · Reply
Nicks_pics
Nicks_pics Oct. 7 at 5:44 PM
$ENLV Link to the D. Boral Capital webinar recording. Recommend listening if you’re invested or considering a position. https://youtu.be/WP3iAXss90g
0 · Reply
Roraon
Roraon Oct. 6 at 8:37 PM
$ENLV Fantastic day for ENLV!!!.
0 · Reply
Stellabella50
Stellabella50 Oct. 6 at 8:22 PM
$ENLV making a little move here.
0 · Reply
THEJSAENZ
THEJSAENZ Oct. 6 at 7:57 PM
$ENLV nice change of pace for this one
0 · Reply
Beebee12
Beebee12 Oct. 3 at 8:16 PM
$ENLV thinking about buying some. Anyone have a price guess here?? Thanks
1 · Reply
GaryGherkins
GaryGherkins Oct. 2 at 1:29 PM
$ENLV was seriously considering an investment here but have had really bad luck with israeli companies in the past. they have a tendency to make a pile of sht sound like your investing in a pile of gold. lost money in every single trade.
1 · Reply
THEJSAENZ
THEJSAENZ Sep. 30 at 7:48 PM
$ENLV pr from todays webinar would be awesome.
2 · Reply
Beebee12
Beebee12 Sep. 30 at 7:11 PM
$ENLV anybody target here?
0 · Reply
JarvisFlow
JarvisFlow Sep. 26 at 11:29 AM
D. Boral Capital updates rating for Enlivex Therapeutics ( $ENLV ) to Buy, target set at 13.
0 · Reply
Rybod30
Rybod30 Sep. 25 at 11:57 AM
$ENLV $2 looks to be tested today. Frustrating hold here, sell a drone to somebody?!?
1 · Reply
tsj555
tsj555 Sep. 21 at 4:29 AM
$ENLV 💩
0 · Reply
BaridBanger
BaridBanger Sep. 19 at 7:31 PM
$ENLV this will make a move soon
0 · Reply
kellymone2
kellymone2 Sep. 18 at 3:25 PM
$ENLV massively undervalued. For me it's a 6$ stock at least
0 · Reply
Mrsdelbusto1
Mrsdelbusto1 Sep. 18 at 12:48 PM
$ENLV
0 · Reply
BULLTRADER0007
BULLTRADER0007 Sep. 17 at 10:46 PM
$ENLV about to take off to the moon, pay attention
1 · Reply
BioTechHealthX
BioTechHealthX Sep. 16 at 8:12 AM
$ENLV Enlivex narrowed its Q2 net loss to $1.87M from $3.1M last year, reducing burn as Allocetra delivers strong clinical wins. https://biotechhealthx.com/biotech-news/enlivex-enlv-reports-1-87m-q2-loss-cuts-cash-burn-nearly-40/
0 · Reply